Your browser doesn't support javascript.
loading
Retrospective Analysis of Retroperitoneal-Abdominal-Pelvic Ganglioneuromas: An International Study by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
Noh, Sangkyu; Nessim, Carolyn; Keung, Emily Z; Roland, Christina L; Strauss, Dirk; Sivarajah, Gausihi; Fiore, Marco; Biasoni, Davide; Cioffi, Stefano Piero Bernardo; Mehtsun, Winta; Cananzi, Ferdinando Carlo Maria; Sicoli, Federico; Quagliuolo, Vittorio; Chen, Jun; Luo, Chenghua; Gladdy, Rebecca A; Swallow, Carol; Johnston, Wendy; Ford, Samuel J; Evenden, Caroline; Tirotta, Fabio; Almond, Max; Nguyen, Laura; Rutkowski, Piotr; Krotewicz, Maria; Pennacchioli, Elisabetta; Cardona, Kenneth; Gamboa, Adriana; Hompes, Daphne; Renard, Marleen; Kollár, Attila; Ryser, Christoph O; Vassos, Nikolaos; Raut, Chandrajit P; Fairweather, Mark; Krakorova, Dagmar Adamkova; Quildrian, Sergio; Perhavec, Andraz; Nizri, Eran; Farma, Jeffrey M; Greco, Stephanie H; Vincenzi, Bruno; Lopez, José Antonio González; Solerdecoll, Mireia Solans; Iwata, Shintaro; Fukushima, Suguru; Kim, Teresa; Tolomeo, Francesco; Snow, Hayden; Howlett-Jansen, Ynez.
Affiliation
  • Noh S; Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, UC San Diego Health Sciences, La Jolla, CA.
  • Nessim C; College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA.
  • Keung EZ; Department of Surgery, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Strauss D; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sivarajah G; Department of Surgical Oncology, Royal Marsden Hospital, London, UK.
  • Fiore M; Department of Surgical Oncology, Royal Marsden Hospital, London, UK.
  • Biasoni D; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cioffi SPB; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Mehtsun W; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cananzi FCM; Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, UC San Diego Health Sciences, La Jolla, CA.
  • Sicoli F; Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Quagliuolo V; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Chen J; Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Luo C; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Gladdy RA; Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Swallow C; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Johnston W; Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China.
  • Ford SJ; Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China.
  • Evenden C; Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Tirotta F; Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Almond M; Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Nguyen L; Midlands Abdominal and Retroperitoneal Sarcoma Unit (MARSU), University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Rutkowski P; Midlands Abdominal and Retroperitoneal Sarcoma Unit (MARSU), University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Krotewicz M; Midlands Abdominal and Retroperitoneal Sarcoma Unit (MARSU), University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Pennacchioli E; Midlands Abdominal and Retroperitoneal Sarcoma Unit (MARSU), University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Cardona K; Department of Surgery, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Gamboa A; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Hompes D; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Renard M; Division of Melanoma, Sarcoma and Rare Tumors, IRCCS, European Institute of Oncology, Milan, Italy.
  • Kollár A; Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA.
  • Ryser CO; Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA.
  • Vassos N; Department of Surgical Oncology, University Hospitals Gasthuisberg, Leuven, Belgium.
  • Raut CP; Department of Paediatric Oncology, University Hospitals, Leuven, Belgium.
  • Fairweather M; Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Krakorova DA; Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Quildrian S; Division of Surgical Oncology, Department of Surgery, Mannheim University Medical Centre, University of Heidelberg, Mannheim, Germany.
  • Perhavec A; Department of Surgery, Brigham and Women's Hospital, Boston, MA.
  • Nizri E; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Farma JM; Harvard Medical School, Boston, MA.
  • Greco SH; Department of Surgery, Brigham and Women's Hospital, Boston, MA.
  • Vincenzi B; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Lopez JAG; Harvard Medical School, Boston, MA.
  • Solerdecoll MS; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Iwata S; Sarcoma and Melanoma Unit, General Surgery Department, Buenos Aires British Hospital, Buenos Aires, Argentina.
  • Fukushima S; Sarcoma and Melanoma Unit, Angel H Roffo Institute of Oncology, University of Buenos Aires, Buenos Aires, Argentina.
  • Kim T; Department of Surgical Oncology, Institute of Oncology Ljubljana, Zaloska, Ljubljana, Slovenia.
  • Tolomeo F; Surgical Oncology Unit, Department of Surgery, The Sackler Faculty of Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel.
  • Snow H; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA.
  • Howlett-Jansen Y; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Ann Surg ; 278(2): 267-273, 2023 08 01.
Article in En | MEDLINE | ID: mdl-35866666
ABSTRACT

OBJECTIVE:

The Transatlantic Australasian Retroperitoneal Sarcoma Working Group conducted a retrospective study on the disease course and clinical management of ganglioneuromas.

BACKGROUND:

Ganglioneuromas are rare tumors derived from neural crest cells. Data on these tumors remain limited to case reports and single-institution case series.

METHODS:

Patients of all ages with pathologically confirmed primary retroperitoneal, intra-abdominal, and pelvic ganglioneuromas between January 1, 2000, and January 1, 2020, were included. We examined demographic, clinicopathologic, and radiologic characteristics, as well as clinical management.

RESULTS:

Overall, 328 patients from 29 institutions were included. The median age at diagnosis was 37 years with 59.1% of patients being female. Symptomatic presentation comprised 40.9% of cases, and tumors were often located in the extra-adrenal retroperitoneum (67.1%). At baseline, the median maximum tumor diameter was 7.2 cm. One hundred sixteen (35.4%) patients underwent active surveillance, whereas 212 (64.6%) patients underwent resection with 74.5% of operative cases achieving an R0/R1 resection. Serial tumor evaluations showed that malignant transformation to neuroblastoma was rare (0.9%, N=3). Tumors undergoing surveillance had a median follow-up of 1.9 years, with 92.2% of ganglioneuromas stable in size. With a median follow-up of 3.0 years for resected tumors, 84.4% of patients were disease free after resections, whereas recurrences were observed in 4 (1.9%) patients.

CONCLUSIONS:

Most ganglioneuromas have indolent disease courses and rarely transform to neuroblastoma. Thus, active surveillance may be appropriate for benign and asymptomatic tumors particularly when the risks of surgery outweigh the benefits. For symptomatic or growing tumors, resection may be curative.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retroperitoneal Neoplasms / Sarcoma / Soft Tissue Neoplasms / Ganglioneuroma / Neuroblastoma Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Ann Surg Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retroperitoneal Neoplasms / Sarcoma / Soft Tissue Neoplasms / Ganglioneuroma / Neuroblastoma Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Ann Surg Year: 2023 Document type: Article Affiliation country: